Timing of debulking surgery in advanced ovarian cancer
暂无分享,去创建一个
I Vergote | K Leunen | P. Neven | I. Vergote | F. Amant | T. Van Gorp | K. Leunen | F Amant | T van Gorp | P Neven | P Berteloot | P. Berteloot | T. Gorp | F. Amant | P. Neven | I. Vergote
[1] Goldie Jh,et al. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979 .
[2] R. Elashoff,et al. Primary Cytoreductive Surgery for Epithelial Ovarian Cancer , 1983, Obstetrics and gynecology.
[3] W. Faught,et al. Primary chemotherapy and adjuvant tumor debulking in the management of advanced‐stage epithelial ovarian cancer , 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
[4] K. Hasumi,et al. [Treatment of stage III and IV ovarian cancer--is neoadjuvant chemotherapy effective?]. , 1993, Nihon Sanka Fujinka Gakkai zasshi.
[5] J. Machiels,et al. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. , 2003, Gynecologic Oncology.
[6] N. Teng,et al. Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival. , 1993, Gynecologic oncology.
[7] D. Atallah,et al. Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] C. Griffiths,et al. Intensive surgical and chemotherapeutic management of advanced ovarian cancer. , 1978, The Surgical clinics of North America.
[9] H. Stettner,et al. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer , 1991, Gynecologic oncology.
[10] B. Karlan,et al. The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery. , 1994, Gynecologic oncology.
[11] E. Fishman,et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography , 2000, Cancer.
[12] N. Spirtos,et al. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? , 2001, Gynecologic oncology.
[13] J. Guastalla,et al. [Advanced ovarian cancer]. , 1995, Soins; la revue de reference infirmiere.
[14] P. V. van Dam,et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. , 1998, Gynecologic oncology.
[15] K. Hatch,et al. Primary surgical therapy of ovarian cancer: how much and when. , 1990, Gynecologic oncology.
[16] J. Thigpen,et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. , 1992, Gynecologic oncology.
[17] P. Schwartz,et al. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] N. Alexander,et al. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? , 1992, American journal of obstetrics and gynecology.
[19] Q. Liu,et al. Cytoreductive surgery for stage IV epithelial ovarian cancer. , 1999, Journal of experimental & clinical cancer research : CR.
[20] D. Chi,et al. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. , 2006, Gynecologic oncology.
[21] J. Green,et al. Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. , 1993, Clinical oncology (Royal College of Radiologists (Great Britain)).
[22] O. Bertetto,et al. The Role of Induction Chemotherapy in Inoperable Ovarian Cancer , 1989, Tumori.
[23] P. Schwartz,et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. , 1999, Gynecologic oncology.
[24] J. Monaghan,et al. Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases. , 2000, Gynecologic oncology.
[25] M. Buyse,et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. , 1995, The New England journal of medicine.
[26] R. Hegazi,et al. Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma , 2005, World journal of surgical oncology.
[27] M. West,et al. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. , 2004, American journal of obstetrics and gynecology.
[28] S. Kehoe,et al. The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma. , 1994, British Journal of Cancer.
[29] M. Parmar,et al. Advanced epithelial ovarian cancer: 1998 consensus statements. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] G. Carta,et al. Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study. , 2002, European journal of gynaecological oncology.
[31] Jason D. Wright,et al. Morbidity of Cytoreductive Surgery in the Elderly , 2003, American journal of obstetrics and gynecology.
[32] D. Hedley,et al. Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] G. Bolis. Randomised comparison of cisplatin with Cyclophosphamide/Cisplatin and with Cyclophosphamide/Doxorubicin/Cisplatin in advanced ovarian cancer , 1988 .
[34] P. Neven,et al. Port‐site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma , 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
[35] S. Perlman,et al. [Neoadjuvant chemotherapy for advanced ovarian cancer]. , 2010, Harefuah.
[36] J H Goldie,et al. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979, Cancer treatment reports.
[37] Y. Hirai,et al. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma. , 2005, Gynecologic oncology.
[38] H. Ngan,et al. QUALITY OF LIFE IN WOMEN TREATED WITH NEOADJUVANT CHEMOTHERAPY FOR ADVANCED OVARIAN CANCER: A PROSPECTIVE LONGITUDINAL STUDY , 2003, International Journal of Gynecologic Cancer.
[39] P. Kolstad,et al. Clinical and Histologic Studies of Ovarian Carcinoma: Long - Term Follow - Up of 990 Cases , 1971, Obstetrics and gynecology.
[40] H. Skipper. Thoughts on cancer chemotherapy and combination modality therapy (1974). , 1974, JAMA.
[41] K. Ushijima,et al. Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer. , 2002, International surgery.
[42] J. Neijt,et al. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives. , 1989, European journal of cancer & clinical oncology.
[43] D. Atallah,et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. , 2003, Journal of the American College of Surgeons.
[44] K. Shiromizu,et al. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. , 2001, Gynecologic oncology.
[45] J. Smith,et al. Rewiew of ovarian cancer at the University of Texas Systems Cancer Center, M.D. Anderson Hospital and Tumor Institute. , 1979, American journal of obstetrics and gynecology.
[46] N. Geller,et al. Prognostic factors in advanced ovarian carcinoma. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] C. Redman,et al. Neoadjuvant (Cytoreductive) Chemotherapy Combined With Intervention Debulking Surgery in Advanced, Unresected Epithelial Ovarian Cancer , 1989, Obstetrics and gynecology.
[48] F. Guidi,et al. Advanced epithelial ovarian cancer: no difference in survival rate between exploratory laparotomy and inadequate debulking surgery as treatment approach before chemotherapy. , 1990, Journal of chemotherapy.
[49] J. Berek,et al. Surgery during chemotherapy and at relapse of ovarian cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[50] H. Kajiyama,et al. Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: Survival benefit and prognostic factors , 2003, International Journal of Gynecologic Cancer.
[51] L. V. Van Hoe,et al. Intraperitoneal contrast material combined with CT for detection of peritoneal metastases of ovarian cancer. , 1998, European journal of gynaecological oncology.
[52] G. Tulunay,et al. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma , 2001, International Journal of Gynecologic Cancer.
[53] J. Neijt,et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] G. Scambia,et al. IMPACT OF INTERVAL DEBULKING SURGERY ON CLINICAL OUTCOME IN PRIMARY UNRESECTABLE FIGO STAGE IIIC OVARIAN CANCER PATIENTS , 2003, International Journal of Gynecologic Cancer.
[55] P. V. van Dam,et al. Ultraradical debulking of epithelial ovarian cancer with the ultrasonic surgical aspirator: a prospective randomized trial. , 1996, American journal of obstetrics and gynecology.
[56] I. Strøyer,et al. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma. , 1987, Gynecologic oncology.
[57] Jeong-Won Lee,et al. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery , 2006, The journal of obstetrics and gynaecology research.
[58] E. van der Velde,et al. The treatment of advanced ovarian carcinoma (I): clinical variables associated with prognosis. , 1988, Gynecologic oncology.
[59] E. Trimble,et al. Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] J. Wharton,et al. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. , 1991, Gynecologic oncology.
[61] Amanda J Hummer,et al. Surgical resection of recurrent endometrial carcinoma. , 2006, Gynecologic oncology.
[62] D. Altomare,et al. NEOADJUVANT CHEMOTHERAPY IN ADVANCED OVARIAN CANCER: A CASE-CONTROL STUDY , 2005, International Journal of Gynecologic Cancer.
[63] P. Morice,et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma , 2001, Cancer.
[64] A. Heintz,et al. Cytoreductive surgery in ovarian carcinoma: Feasibility and morbidity , 1986 .